Evidence map›Paper›PMID 38619586›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2024

Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience.

Nurşah Eker, Gülnur Tokuç, Alican Sarısaltık, Adnan Dağçınar, Dilek Gül, Beste Melek Atasoy, Barış Yılmaz, Burcu Tufan Taş

Abstract read
PubMed Publisher
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nurşah EkerDepartment of Pediatric Hematology Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey. nursaheker@hotmail.com.ORCID 0000-0002-7707-3035
Gülnur TokuçDepartment of Pediatric Hematology Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Alican SarısaltıkRepublic of Turkey Ministry of Health, Cayırova District Health Directorate, Kocaeli, Turkey.
Adnan DağçınarDepartment of Neurosurgery, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Dilek GülDepartment of Radiation Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Beste Melek AtasoyDepartment of Radiation Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Barış YılmazDepartment of Pediatric Hematology Oncology, Pendik Education and Research Hospital, Marmara University, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Burcu Tufan TaşDepartment of Pediatric Hematology Oncology, Pendik Education and Research Hospital, Marmara University, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
Marmara University · TRMinistry of Health · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChildren under 3 years old represent a notable portion, about 25 to 30%, of all central nervous system tumor (CNS) cases. Their clinical course, prognosis, and treatment significantly differ from older children. This single-center retrospective study aims to comprehensively analyze survival factors in children under three diagnosed with CNS tumors.

methodsBetween April 2012 and December 2023, cases under 3 years of age with CNS tumors diagnosed at our center were retrospectively evaluated.

resultsAmong 279 CNS tumor cases, 42 (15%) were evaluated. The 5-year overall and event-free survival rates were 67.4% (95% CI 47.5-81.1) and 39.8% (95% CI 24.2-55.0), respectively. Gender, symptom onset to diagnosis time, pathological neurological findings at diagnosis, and tumor location did not significantly impact survival (p > 0.05). However, cases with neurological symptoms showed significantly higher event-free survival rates (p < 0.05). Patients with embryonal tumors, metastases, inability for total surgical excision, relapsed/progressive diseases, and who under 1 year old had significantly lower survival rates (p < 0.05). Radiotherapy timing did not affect survival (p > 0.05). Event-free survival rates remained unchanged after the third year.

conclusionThe current treatments have been observed to have a positive impact on survival rates. Nonetheless, there is a need for novel treatments for patients with embryonal tumors, metastases, aged under 1 year, and those where total surgical excision is not feasible or in cases with progressive/relapse disease. This study underscores the importance of the first 3 years regarding relapse, progression, or mortality risk.

Indexed as

Central Nervous System NeoplasmsChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesSurvival RateTreatment OutcomeBrain tumorsChildrenInfancySurvival

Identifiers

PMID38619586
OpenAlexW4394812464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.